- Home
- WFF vs QNCX Comparison
WFF vs QNCX Comparison
Compare WFF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFF | QNCX |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 17.5M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WFF | QNCX |
|---|---|---|
| Price | $2.41 | $31.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 446.2K | 15.4K |
| Earning Date | 05-24-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.08 |
| 52 Week High | $10.71 | $35.41 |
Technical Indicators
Market Signals| Indicator | WFF | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 62.61 | 53.67 |
| Support Level | $1.78 | $29.95 |
| Resistance Level | $2.47 | $35.38 |
| Average True Range (ATR) | 0.24 | 2.10 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 57.34 | 65.49 |
Price Performance
Historical ComparisonAbout WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings, and other custom-made FRP products. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance. Geographically, the company generates the majority of its revenue from Australia.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.